Imunon, Inc. Common Stock
IMNNImmunoGen, Inc. (IMNN) is a biotechnology company focused on the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. The company leverages its proprietary ADC technology to create therapies designed to deliver potent cancer-killing agents directly to tumor cells, aiming to improve efficacy and reduce side effects associated with traditional chemotherapy.
Company News
IMUNON announced progress in its Phase 3 OVATION 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer. The company has enrolled its first patient, implemented cost conservation measures, and introduced a 15% stock dividend to shareholders.
IMUNON, a clinical-stage biotechnology company, announced a $3.25 million private placement and the potential for an additional $6.5 million from the exercise of short-term warrants. The company plans to use the proceeds for working capital and general corporate purposes.
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in ad...
